Corcept Therapeutics Incorporated  

(Public, NASDAQ:CORT)   Watch this stock  
Find more results for CORT
+0.63 (5.40%)
May 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.78 - 12.36
52 week 4.95 - 12.40
Open 11.78
Vol / Avg. 1.26M/1.09M
Mkt cap 1.47B
P/E 116.50
Div/yield     -
EPS 0.11
Shares 113.19M
Beta 1.76
Inst. own 60%
Jul 31, 2017
Q2 2017 Corcept Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 6, 2017
Corcept Therapeutics Inc at Jefferies Healthcare Conference Add to calendar
May 24, 2017
Corcept Therapeutics Inc Annual Shareholders Meeting
May 16, 2017
Corcept Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference
May 1, 2017
Q1 2017 Corcept Therapeutics Inc Earnings Call
May 1, 2017
Q1 2017 Corcept Therapeutics Inc Earnings Release
Mar 6, 2017
Q4 2016 Corcept Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 15.90% 10.01%
Operating margin 17.17% 12.52%
EBITD margin - 12.62%
Return on average assets 24.43% 13.49%
Return on average equity 38.70% 27.19%
Employees 103 -
CDP Score - -


149 Commonwealth Dr
MENLO PARK, CA 94025-1133
United States - Map
+1-650-3273270 (Phone)
+1-650-3273218 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

Officers and directors

James N. Wilson Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Joseph K. Belanoff M.D. President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Gary Charles Robb Chief Financial Officer, Chief Accounting Officer, Secretary
Age: 52
Bio & Compensation  - Reuters
Renee D. Gala Director
Age: 43
Bio & Compensation  - Reuters
Len L. Baker Jr. Independent Director
Age: 62
Bio & Compensation  - Reuters
Daniel Mark Bradbury Independent Director
Age: 55
Bio & Compensation  - Reuters
Joseph C. Cook Jr. Independent Director
Age: 73
Bio & Compensation  - Reuters
Patrick G. Enright Independent Director
Age: 54
Bio & Compensation  - Reuters